BioCryst Pharmaceuticals, Inc.

BCRX

US09058V1035

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 16:00:00 2024-07-05 EDT			5-day change	1st Jan Change
6.52 ^USD	+1.72%		+5.50%	+8.85%

07-03	Island Pharmaceuticals Acquiring Clinical-Stage Antiviral Molecule	MT
07-01	BioCryst Pharmaceuticals, Inc.(NasdaqGS:BCRX) dropped from Russell Small Cap Comp Value Index	CI

BioCryst Pharmaceuticals, Inc.(NasdaqGS:BCRX) dropped from Russell 2500 Value Index

July 30, 2024

Latest news about BioCryst Pharmaceuticals, Inc.

Island Pharmaceuticals Acquiring Clinical-Stage Antiviral Molecule	07-02	MT
BioCryst Pharmaceuticals, Inc.(NasdaqGS:BCRX) dropped from Russell Small Cap Comp Value Index	06-30	CI
BioCryst Pharmaceuticals, Inc.(NasdaqGS:BCRX) dropped from Russell 2500 Value Index	06-30	CI
BioCryst Pharmaceuticals, Inc.(NasdaqGS:BCRX) dropped from Russell 3000 Value Index	06-30	CI
BioCryst Pharmaceuticals, Inc.(NasdaqGS:BCRX) dropped from Russell 2000 Value Index	06-30	CI
BioCryst Pharmaceuticals, Inc.(NasdaqGS:BCRX) dropped from Russell 3000E Value Index	06-30	CI
BioCryst Pharmaceuticals Says Drug Shows Evidence of Reducing Attacks Among Hereditary Angioedema Patients	06-03	MT
Transcript : BioCryst Pharmaceuticals, Inc. Presents at Bank of America Health Care Conference 2024, May-15-2024 02:20 PM	05-15
Sector Update: Health Care Stocks Advance Late Wednesday Afternoon	05-15	MT
BioCryst Pharmaceuticals Shares Rise 20% Following Disclosure of Executive Share Purchases	05-15	MT
BioCryst Says Orladeyo Granted Approval in Mexico	05-13	MT
BioCryst Pharmaceuticals, Inc. Announces Federal Commission for Protection Against Health Risks in Mexico Grants Approval for Oral, Once-Daily ORLADEYO	05-13	CI
BioCryst Presents New Real-world Evidence Showing Significant Reductions in Healthcare Resource Utilization Among Patients with HAE Following Initiation of ORLADEYO	05-09	CI
JMP Securities Adjusts Price Target on BioCryst Pharmaceuticals to $15 From $14, Maintains Market Outperform Rating	05-07	MT
Sector Update: Health Care Stocks Higher in Late Afternoon Trading	05-06	MT
BioCryst Pharmaceuticals Shares Jump After Q1 Beat	05-06	MT
Transcript : BioCryst Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 06, 2024	05-06
Biocryst Pharmaceuticals, Inc. Revises Revenue Guidance for the Year 2024	05-06	CI
BioCryst Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-06	CI
North American Morning Briefing : Stock Futures Rise as Hopes of Rate Cut Return	05-06	DJ
BioCryst Pharmaceuticals Secures Approval for Orladeyo in Brazil	04-17	MT
BioCryst Pharmaceuticals, Inc. Announces Approval of ORLADEYO (berotralstat) by the Brazilian Health Regulatory Agency	04-17	CI
Transcript : BioCryst Pharmaceuticals, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-12-2024 07:30 AM	03-12
Transcript : BioCryst Pharmaceuticals, Inc., Q4 2023 Earnings Call, Feb 26, 2024	02-26
BioCryst Pharmaceuticals Q4 Adjusted Loss Narrows as Revenue Increases	02-26	MT

Chart BioCryst Pharmaceuticals, Inc.

Duration

Period

More charts

BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on improving the lives of people living with complement-mediated and other rare diseases. The Company leverages its expertise in designing to develop first-in-class oral small-molecule and protein therapeutics to target difficult-to-treat diseases. Its marketed products include oral, once-daily ORLADEYO for the prevention of hereditary angioedema (HAE) attacks and RAPIVAB (peramivir injection) for the treatment of acute uncomplicated influenza in the United States. Its other products and product candidates include BCX10013, RAPIACTA (peramivir injection), PERAMIFLU (peramivir injection), and early-stage discovery programs. BCX10013, is a potent and specific Factor D inhibitor. RAPIACTA focuses on uncomplicated seasonal influenza. RAPIVAB (peramivir injection) is approved in the United States for the treatment of acute uncomplicated influenza for patients six months and older.

Sector

Biotechnology & Medical Research

Calendar

2024-07-31 - Q2 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for BioCryst Pharmaceuticals, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

6.52 USD

Average target price

14 USD

Spread / Average Target

+114.72%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
BIOCRYST PHARMACEUTICALS, INC.	+8.85%	1.35B
VERTEX PHARMACEUTICALS INCORPORATED	+16.61%	122B
REGENERON PHARMACEUTICALS, INC.	+17.75%	112B
ARGENX SE	+17.23%	25.91B
BIONTECH SE	-24.11%	19.33B
GENMAB A/S	-18.56%	16.17B
BEIGENE, LTD.	-18.47%	15.6B
WUXI APPTEC CO., LTD.	-47.75%	14.65B
SAREPTA THERAPEUTICS, INC.	+57.35%	14.34B
NEUROCRINE BIOSCIENCES, INC.	+5.62%	14B

Bio Therapeutic Drugs